我院2014～2016年辅助用药注射剂使用分析

Analysis of the utilization of adjuvant drug injections from 2014 to 2016 in our hospital

目的了解常熟市第一人民医院(以下简称"我院")辅助用药应用现状和趋势,为临床合理用药提供参考。方法依据江苏省苏州市及南京市卫计委辅助用药重点监控目录,从我院HIS中调取2014~2016年辅助用药注射剂相关数据,按照WHO推荐的限定日剂量法,对辅助用药注射剂的销售金额、年增长率、用药频度、排序比和限定日费用等进行统计分析。结果 3年期间,我院辅助用药注射剂的销售金额分别为7084.82、6350.41、4987.39万元,2015、2016年各比上年下降10.37%和21.46%,占医院药品销售总金额的比例为19.64%、16.52%和12.94%。销售金额和DDDs排序第1、2位类别是神经系统用药和免疫调节药。单品种销售金额排序列前3位的有神经节苷脂、鼠神经生长因子和依达拉奉等;单品种用药频度排序列前3位的是香菇多糖、脂溶性维生素(Ⅱ)和前列地尔。结论我院辅助用药注射剂使用大幅下降,管控成效显著。但仍需对性价比较差的辅助用药进行重点跟踪,进一步促进其合理使用。

Objective To understand the current situation and development trend of the adjuvant drug injections in Changshu NO.1 People ′s Hospital（ ＂our hospital ＂ for short）, so as to provide reference for clinical rational use of the drugs. Methods According to the key monitoring directory of adjuvant drug injections issued by Suzhou and Nanjing Health and Family Planning Commission of Jiangsu Province, the relevant data of adjuvant drug injection from2014 to 2016 was collected from HIS. The consumption sum, annual growth rate, defined daily dose system（DDDs）,sorting ratio and defined daily cost（DDC） of the adjuvant drug injections were statistically analyzed according to the limited daily dose recommend to WHO. Results During 3 years, the consumption sum of adjuvant drug injections each were 70.8482, 63.5041 and 49.8739 million yuan. The consumption sum of adjuvant drug injections of 2015 and 2016 declined by 10.37% and 21.46% compared with last year. The proportion of consumption sum of adjuvant drug injections in all drugs were 19.64% in 2014, 16.52% in 2015 and 12.94% in 2016. The first and second categories of consumption sum and DDDs rank were neurological drugs and immunomodulating drugs. The top 3 varieties of single item of consumption sum were ganglioside, mouse nerve growth factor and Edaravone. The top 3 varieties of single item of DDDs were lentinan, fat-soluble vitamin（Ⅱ） and Alprostadil. Conclusion The use of adjuvant drug injections in our hospital has dropped drastically, and the effectiveness of management and control is remarkable. However, it still needs to focus on the adjuvant drugs with poor cost performance to further promote their rational use.